Ozempic, Wegovy get new warning over potential vision loss: Should patients be worried?
Last Updated : Nov 17 2026 | 6:19 PM IST
The US Food and Drug Administration (FDA) is requiring new safety warnings on popular GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, over a potential risk of a rare eye condition called Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), which can cause permanent vision loss. The regulator reviewed 126 clinical trials and identified roughly six cases per 100,000 patient-years among users. The risk remains rare. Patients should watch for sudden, painless vision loss, blurred vision or blind spots and seek immediate medical attention.